SBK & ASA biomechanically safer than LASIK

Article

With regards to maintaining corneal biomechanics, sub-Bowman's keratomileusis (SBK) and advanced surface ablation (ASA) are improvements over conventional LASIK.

With regards to maintaining corneal biomechanics, sub-Bowman's keratomileusis (SBK) and advanced surface ablation (ASA) are improvements over conventional LASIK, according to a report published in the January issue of the Journal of Refractive Surgery.

Daniel Dawson and colleagues from Emory University and Emory Vision, Atlanta, Georgia, USA conducted histologic, ultrastructual and cohesive tensile strength evaluations on 25 normal human corneal specimens, 206 uncomplicated LASIK specimens, 17 uncomplicated SBK specimens, four uncomplicated PRK specimens, two uncomplicated ASA specimens, five keratoconus specimens, 12 postoperative LASIK ectasia specimens and one postoperative PRK ectasia specimen compared with previously published studies.

The researchers found that histological and ultrastructual studies of normal corneas revealed significant differences in the direction of collagen fibrils and/or the degree of lamellar interweaving in Bowman's layer, the anterior third of the corneal stroma, the posterior two-thirds of the corneal stroma and Descemet's membrane. Cohesive tensile strength testing supported these findings, as the stronger, more rigid regions of the cornea were located anteriorly and peripherally.

These results suggest that ASA, and secondarily SBK, should be biomechanically safer than conventional LASIK with regard the risk of causing keratectasia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.